(the "Form 10-K") and other periodic reports filed with the SEC, including the following: (i) risks related to the long, expensive and uncertain clinical development and regulatory process, including having no unexpected safety, toxicology, clinical or other issues or delays in anticipated timing of the regulatory approval process; (ii) risks related to failure to achieve the clinical trial results required to commercialize our product candidates; and (iii) risks related to timely patient enrollment and retention in clinical trials. The risks and other factors discussed above should be considered only in connection with the fully discussed risks and other factors discussed in detail in the Form 10-K and InterMune's other periodic reports filed with the SEC, all of which are available via InterMune's web site at
www.intermune.com.
Pegasys(R) and Copegus(R) are registered trademarks of Roche.
'/>"/>SOURCE InterMune, Inc. Copyright©2009 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 Related medicine news :1.
InterMune to Present at Thomas Weisel Partners Healthcare Conference2.
Former InterMune CEO W. Scott Harkonen Indicted for Wire Fraud and FDA Violations3.
InterMune to Present at the 2008 Wachovia Healthcare Conference4.
Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs5.
LegalView Reports Traumatic Brain Injury Study Concluding Spirituality Increases Following Brain Damage6.
Allscripts Reports Fiscal 2009 Second Quarter Results7.
MDS Reports Final Fourth-Quarter 2008 Results8.
Consumer Reports: Big Promises of Some Infomercial Exercise Machines Fall Flat; Plus, Set Up a Home Gym for Under $1009.
Cardium Reports on Exchange Listing With NYSE Alternext US10.
CellCyte Genetics Corporation: Seattle Times Erroneously Reports That CellCyte Closes11.
Joint Commission Reports Positive Survey Results for CHA